Navigation Links
Genetic marker may predict early onset of prostate cancer
Date:5/15/2009

ORLANDO (May 15, 2009)Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.

Veda Giri, M.D., a medical oncologist and director of the Prostate Cancer Risk Assessment Program at Fox Chase, will present the data at the annual meeting of the American Society of Clinical Oncology on Saturday, May 30.

"Genetic testing for prostate cancer is not yet clinically well characterized as it is for breast, ovarian cancer and colon cancer," Giri says. "Markers such as this one are useful because they may help clinicians distinguish between men who are at risk for earlier onset of disease where intensive screening approaches can be discussed. Men who do not carry genetic markers of risk may not need such screening measures."

More than half of all prostate tumors carry a fusion gene called, TMPRSS2-ERG, which may have a role in prostate cancer formation. Recently, scientists reported that a single nucleotide polymorphism, called the Met160Val SNP (also referred to as rs12329760), is associated with the gene fusion. Specifically, prostate cancer patients who carry the T allele of Met160Val are more likely to have a prostate tumor with the gene fusion than patients who have the C allele.

To find out if the T allele is clinically relevant in men who are at high risk of developing prostate cancer but do not yet have the disease, Giri and colleagues genotyped 631 men enrolled in the Prostate Cancer Risk Assessment Program at Fox Chase. Overall, while there were differences in the distribution of the alleles by race, the risk allele did not have a major contribution to disease in 400 African American men or in 231 Caucasian men with a family history of prostate cancer. They then evaluated this marker in 183 Caucasian men who have a family history of prostate cancer undergoing follow-up in the Prostate Cancer Risk Assessment Program. They found that the high risk allele was associated with a 2.5-fold increased risk of developing prostate cancer, relative to the low risk allele. Additionally, more men carrying the high risk allele developed prostate cancer earlier than men not carrying the risk allele.

"We need longer follow-up to know the precise time frame for cancer development, but we have learned some information on the difference in time to diagnosis from this study," Giri says.

According to Giri, a similar association between the T allele and disease may exist in African American men with a family history of prostate cancer, however, there were not enough of these men in the study to test the possibility.

"This was a pilot study," Giri says. "We are expanding the study to see if the association holds up in a larger Caucasian patient population. We are also planning collaborations with investigators at other institutions to test if this marker would be informative in African American men with a family history."


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: